AstraZeneca said Tuesday it has agreed to provide up to half a million additional doses of its experimental Covid-19 antibody-based combination treatment to the United States for $ 205 million.
In October, the Anglo-Swedish pharmaceutical company and US government agencies initially agreed to supply 200,000 doses. The extension increases the potential US supply of treatment to 700,000 doses and the total value of the deal to $ 726 million
AstraZeneca said the AZD7442 treatment is a combination of two monoclonal antibodies and has not yet been approved for use, adding that the new agreement depends on FDA approval.
The company said it did not expect any changes to its 2021 forecast due to the deal.